Swiss newco Arvelle Therapeutics has baged a $180m (159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (88.4m) upfront from SK Biopharmaceuticals.
The market for bio-based building blocks and polymers showed moderate growth to 7.5 million tonnes in 2018 and will grow with a CGAR of 4% by 2023 reports German nova-Institute.
Swiss researchers have demonstrated a way to cure type I diabetes without cell transplantation. In model mice the reprogrammed non-islet cells from human pancreas
Biotech Campus Delft, Royal DSM and YES!Delft partner up have launched a Biotech Validation Lab to validate the business concepts of European biotech startups.
Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Immunotherapeutics has got the first milestone payment within its 272m deal with Servier inked in 2016.
Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Jennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.
Sosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
EMAs human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.